Cabot (CBT) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
3 Nov, 2026Executive summary
FY26 adjusted EPS was $6.42 versus diluted EPS of $4.02; Q4 adjusted EPS was $1.61 versus diluted EPS of $1.25.
FY27 adjusted EPS guidance is $6.15–$6.75 amid variable demand scenarios and ongoing Reinforcement Materials customer negotiations.
Q4 Performance Chemicals EBIT rose 43% YoY to $60M, while Reinforcement Materials EBIT declined 27% to $87M.
Financial highlights
Q4 net sales were $1,009M versus $899M YoY; FY26 net sales were $3,744M versus $3,713M.
Q4 net income attributable to Cabot was $66M versus $43M YoY; FY26 net income was $213M versus $331M.
Q4 operating cash flow was $143M and discretionary free cash flow was $117M; FY26 operating cash flow was $421M.
FY26 operating income was $477M versus $621M; adjusted EBITDA was $735M versus $804M.
Outlook and guidance
FY27 adjusted EPS guidance is $6.15–$6.75, with a 28%–30% operating tax rate and $200M–$230M of capital expenditures.
FY27 modeling assumptions include interest expense of $73M–$77M, general unallocated income of $28M–$36M, and share repurchases of $150M–$250M.
Q1 FY27 Reinforcement Materials EBIT is expected to improve modestly sequentially but decline YoY; Performance Chemicals EBIT is expected lower sequentially but higher YoY.
Battery Materials EBITDA is expected in the high $40M range in FY27, up from $43M in FY26; new capacity is expected to contribute from FY28.
FY27 outlook anticipates favorable free cash flow, with higher volumes expected in battery materials, electronics and strategic accounts.
Latest events from Cabot
- Q3 adjusted EPS up 4%, guidance tightened, and CEO transition set for October 2026.CBT
Q3 2026 - Q2 Adjusted EPS was $1.61, with battery materials growth and major restructuring actions.CBT
Q2 2026 - Adjusted EPS down 13% to $1.53; Battery Materials up 39%, Reinforcement Materials EBIT down 22%.CBT
Q1 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.CBT
Proxy Filing - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong ESG focus.CBT
Proxy Filing - FY24 adjusted EPS guidance raised to $7.00–$7.10, driven by battery, E2C, and inkjet growth.CBT
Investor Day 2024 - Q3 adjusted EPS up 35% year-over-year; FY2024 guidance raised on strong segment growth.CBT
Q3 2024 - 31% EPS growth, $265M returned to shareholders, and 2025 EPS guidance of $7.40–$7.80.CBT
Q4 2024 - Adjusted EPS up 13% to $1.76; net income and cash flow drive strong shareholder returns.CBT
Q1 2025